7 completed, 3 recruiting, 1 terminated. 5 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 2 |
| Phase 3 | 3 | Recruiting 2, Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Lymphatic Malformations: new trials by email Literature Review of Lymphatic Malformations trials Research Report on Lymphatic Malformations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome KP-001, Placebo - Venous Malformations, Lymphatic Malformations | Phase 3 | Recruiting | Kaken Pharmaceutical | 150 | 2026-05-13 | 2026-11-12 |
| A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) RLY-2608, Placebo - PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations | Phase 2 | Recruiting | Relay Therapeutics, Inc. | 277 | 2025-06-13 | 2026-11-12 |
| Bleomycin Intralesional Injections of Cystic Hygromas Intralesional Injections - Lymphatic Malformations | Not applicable | Completed | Delta University for Science and Technology | 30 | 2024-09-01 | 2026-04-28 |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. Alpelisib, Placebo - Lymphatic Malformations | Phase 2 / Phase 3 | Recruiting | Novartis Pharmaceuticals | 232 | 2023-11-24 | 2026-10-09 |
| Bleomycin as an Effective and Curative Adjunct Therapy for Lymphangioma Sclerotherapy with intralesional bleomycin injection - Lymphangioma, Lymphatic Malformations | Completed | National Children's Hospital, Vietnam | 809 | 2018-01-01 | 2025-04-24 | |
| Sildenafil for the Treatment of Lymphatic Malformations Sildenafil 20 mg tablets, Placebo tablets (resembling Revatio) - Lymphatic Malformations, Lymphatic Diseases | Phase 2 | Completed | Stanford University | 22 | 2015-05-23 | 2022-11-17 |
| Selenium in the Treatment of Complicated Lymphatic Malformations Selenium - Lymphatic Malformations | Phase 1 | Terminated | Medical College of Wisconsin | 5 | 2010-09-01 | 2013-04-23 |
| Diagnosis of Hemangiomas and Vascular Malformations Hemangiomas, Vascular Malformations | Completed | University of Arkansas | 56 | 2007-02-01 | 2012-10-26 | |
| OK432 (Picibanil) in the Treatment of Lymphatic Malformations OK432 - Lymphatic Malformations | Phase 2 | Completed | Richard JH Smith | 275 | 2005-10-05 | 2021-11-23 |
| Airway Vascular Lesions Protocols for Treatment - Hemangiomas, Venous Malformations | Completed | University of Arkansas | 75 | 2002-12-01 | 2019-01-11 | |
| Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations picibanil - Lymphatic Malformations | Phase 2 / Phase 3 | Completed | University of Iowa | 150 | 2000-04-01 | 2015-03-25 |
Lymphatic Abnormalities (11) · Lymphangioma (3) · Lymphangioma, Cystic (3) · Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi (2) · Hemangioma (2) · Klippel-Trenaunay-Weber Syndrome (2) · Vascular Malformations (2) · Arteriovenous Malformations (1) · Disease (1) · Lymphatic Diseases (1) · Megalencephaly cutis marmorata telangiectatica congenita (1)
Congenital Abnormalities (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Hemic and Lymphatic Diseases (11) · Lymphatic Diseases (10) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasm, Lymphatic Tissue (4) · Cardiovascular Diseases (3) · Vascular Diseases (3) · Angiomatosis (2) · Cardiovascular Abnormalities (2) · Neoplasms, Vascular Tissue (2) · Lymphangioma (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Picibanil (2) · Alpelisib (1) · Injections, Intralesional (1) · Sclerotherapy (1) · Selenium (1) · Sildenafil Citrate (1) · Therapeutics (1)
University of Arkansas (2) · Delta University for Science and Technology (1) · Kaken Pharmaceutical (1) · Medical College of Wisconsin (1) · National Children's Hospital, Vietnam (1) · Novartis Pharmaceuticals (1) · Relay Therapeutics, Inc. (1) · Richard JH Smith (1) · Stanford University (1) · University of Iowa (1)
United States (7) · Australia (2) · Belgium (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Czechia (1) · Egypt (1) · Ireland (1) · Netherlands (1) · Norway (1) · South Korea (1)
Gal Shafirstein, Ph.D. (1) · Gresham T Richter, M.D. (1) · Jessica L Boswell (1) · Jessica L Boswell, BS, CRS (1) · Joyce Teng, MD, PhD (1) · Michael E Kelly, MD, PhD (1) · Quang T Nguyen, M.D. (1) · Richard J Smith (1) · Richard JH Smith, MD (1)
PMID 11527161, PMID 16418953, PMID 19117316, PMID 19407619, PMID 20843632, PMID 25682445, PMID 29456959, PMID 29928081, PMID 32139985, PMID 33059994, PMID 33625132
2023 (1)